BioXcel Therapeutics, Inc. (BTAI) — AI Analysis & Mentions

BioXcel Therapeutics has faced challenges with decreased net revenue and rising R&D expenses. However, as the company advances late-stage clinical programs, the long-term value seems promising if these trials yield positive results. Investors should remain wary but alert to potential upsides as more information becomes available.